Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis

Tomoomi Nagakane, Toshio Ogura, Koji Nishiya, Masamitsu Natsumeda, Toshinori Haramoto, Toru Sasaki, Yasuyuki Ooyama, Hirofumi Makino, Syuzo Hirakawa, Shinya Suzuki, Zensuke Ota

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bucillamine is a compound of tiopronin which has anti-rheumatic action pharmacologically based on the similar chemical structure of D-penicillamine. We studied the clinical profile and the precise histological and immunological changes in kidney tissue in five patients with rheumatoid arthritis (RA) who had the profound proteinuria along with the bucillamine (BU) therapy. There was no specific predisposition for BU-induced proteinuria in clinical profiles of five RA patients as age, disease duration, disease activity and co-given drugs except that all of patients were female. Urinalysis revealed proteinuria in all 5 patients (2 patients : nephrotic syndrome) and microscopic hematuria in 4 out of 5 of patients. Renal failure was not observed in all patients. The renal biopsy was performed in 4 patients. The histological findings by light microscopy, fluorescent antibody technique and electron microscopy demonstrated membranous glomerulonephritis (MGN), i.e. positive staining of IgG and electron dense subepithelial deposits in glomerular basement membrane (GBM). Nevertheless, the number of subepithelial deposits in GBM was smaller and the location was scattered compared with idiopathic MGN. The total dosis of BU administration in these patients varied from 7.9 g to 128 g (average : 41.6 g). The causes of BU-induced nephropathy were not known. DLST by BU was, however, positive in 2 out of 5 patients. The outcome of BU-induced proteinuria seemed to be good since one of the patients had the renal failure and the amount of proteinuria was decreased or disappeared by steroid therapy or discontinuation of BU. Thus, the abnormal responses of cellular immunity to this drug might involve in the development of BU-nephropathy.

Original languageEnglish
Pages (from-to)346-355
Number of pages10
JournalJapanese Journal of Clinical Immunology
Volume13
Issue number4
DOIs
Publication statusPublished - Jan 1 1990

Fingerprint

Rheumatoid Arthritis
Proteinuria
Membranous Glomerulonephritis
Glomerular Basement Membrane
Renal Insufficiency
bucillamine
Tiopronin
Kidney
Penicillamine
Urinalysis
Nephrotic Syndrome
Hematuria
Cellular Immunity
Pharmaceutical Preparations
Fluorescent Antibody Technique
Microscopy
Electron Microscopy
Immunoglobulin G
Steroids
Electrons

Keywords

  • bucillamine
  • membranous glomerulonephritis
  • proteinuria
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Nagakane, T., Ogura, T., Nishiya, K., Natsumeda, M., Haramoto, T., Sasaki, T., ... Ota, Z. (1990). Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis. Japanese Journal of Clinical Immunology, 13(4), 346-355. https://doi.org/10.2177/jsci.13.346

Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis. / Nagakane, Tomoomi; Ogura, Toshio; Nishiya, Koji; Natsumeda, Masamitsu; Haramoto, Toshinori; Sasaki, Toru; Ooyama, Yasuyuki; Makino, Hirofumi; Hirakawa, Syuzo; Suzuki, Shinya; Ota, Zensuke.

In: Japanese Journal of Clinical Immunology, Vol. 13, No. 4, 01.01.1990, p. 346-355.

Research output: Contribution to journalArticle

Nagakane, T, Ogura, T, Nishiya, K, Natsumeda, M, Haramoto, T, Sasaki, T, Ooyama, Y, Makino, H, Hirakawa, S, Suzuki, S & Ota, Z 1990, 'Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis', Japanese Journal of Clinical Immunology, vol. 13, no. 4, pp. 346-355. https://doi.org/10.2177/jsci.13.346
Nagakane, Tomoomi ; Ogura, Toshio ; Nishiya, Koji ; Natsumeda, Masamitsu ; Haramoto, Toshinori ; Sasaki, Toru ; Ooyama, Yasuyuki ; Makino, Hirofumi ; Hirakawa, Syuzo ; Suzuki, Shinya ; Ota, Zensuke. / Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis. In: Japanese Journal of Clinical Immunology. 1990 ; Vol. 13, No. 4. pp. 346-355.
@article{28c67572ee97430db122a027d8f7bee3,
title = "Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis",
abstract = "Bucillamine is a compound of tiopronin which has anti-rheumatic action pharmacologically based on the similar chemical structure of D-penicillamine. We studied the clinical profile and the precise histological and immunological changes in kidney tissue in five patients with rheumatoid arthritis (RA) who had the profound proteinuria along with the bucillamine (BU) therapy. There was no specific predisposition for BU-induced proteinuria in clinical profiles of five RA patients as age, disease duration, disease activity and co-given drugs except that all of patients were female. Urinalysis revealed proteinuria in all 5 patients (2 patients : nephrotic syndrome) and microscopic hematuria in 4 out of 5 of patients. Renal failure was not observed in all patients. The renal biopsy was performed in 4 patients. The histological findings by light microscopy, fluorescent antibody technique and electron microscopy demonstrated membranous glomerulonephritis (MGN), i.e. positive staining of IgG and electron dense subepithelial deposits in glomerular basement membrane (GBM). Nevertheless, the number of subepithelial deposits in GBM was smaller and the location was scattered compared with idiopathic MGN. The total dosis of BU administration in these patients varied from 7.9 g to 128 g (average : 41.6 g). The causes of BU-induced nephropathy were not known. DLST by BU was, however, positive in 2 out of 5 patients. The outcome of BU-induced proteinuria seemed to be good since one of the patients had the renal failure and the amount of proteinuria was decreased or disappeared by steroid therapy or discontinuation of BU. Thus, the abnormal responses of cellular immunity to this drug might involve in the development of BU-nephropathy.",
keywords = "bucillamine, membranous glomerulonephritis, proteinuria, rheumatoid arthritis",
author = "Tomoomi Nagakane and Toshio Ogura and Koji Nishiya and Masamitsu Natsumeda and Toshinori Haramoto and Toru Sasaki and Yasuyuki Ooyama and Hirofumi Makino and Syuzo Hirakawa and Shinya Suzuki and Zensuke Ota",
year = "1990",
month = "1",
day = "1",
doi = "10.2177/jsci.13.346",
language = "English",
volume = "13",
pages = "346--355",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Immunopathological study of bucillamine induced nephropathy in patients with rheumatoid arthritis

AU - Nagakane, Tomoomi

AU - Ogura, Toshio

AU - Nishiya, Koji

AU - Natsumeda, Masamitsu

AU - Haramoto, Toshinori

AU - Sasaki, Toru

AU - Ooyama, Yasuyuki

AU - Makino, Hirofumi

AU - Hirakawa, Syuzo

AU - Suzuki, Shinya

AU - Ota, Zensuke

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Bucillamine is a compound of tiopronin which has anti-rheumatic action pharmacologically based on the similar chemical structure of D-penicillamine. We studied the clinical profile and the precise histological and immunological changes in kidney tissue in five patients with rheumatoid arthritis (RA) who had the profound proteinuria along with the bucillamine (BU) therapy. There was no specific predisposition for BU-induced proteinuria in clinical profiles of five RA patients as age, disease duration, disease activity and co-given drugs except that all of patients were female. Urinalysis revealed proteinuria in all 5 patients (2 patients : nephrotic syndrome) and microscopic hematuria in 4 out of 5 of patients. Renal failure was not observed in all patients. The renal biopsy was performed in 4 patients. The histological findings by light microscopy, fluorescent antibody technique and electron microscopy demonstrated membranous glomerulonephritis (MGN), i.e. positive staining of IgG and electron dense subepithelial deposits in glomerular basement membrane (GBM). Nevertheless, the number of subepithelial deposits in GBM was smaller and the location was scattered compared with idiopathic MGN. The total dosis of BU administration in these patients varied from 7.9 g to 128 g (average : 41.6 g). The causes of BU-induced nephropathy were not known. DLST by BU was, however, positive in 2 out of 5 patients. The outcome of BU-induced proteinuria seemed to be good since one of the patients had the renal failure and the amount of proteinuria was decreased or disappeared by steroid therapy or discontinuation of BU. Thus, the abnormal responses of cellular immunity to this drug might involve in the development of BU-nephropathy.

AB - Bucillamine is a compound of tiopronin which has anti-rheumatic action pharmacologically based on the similar chemical structure of D-penicillamine. We studied the clinical profile and the precise histological and immunological changes in kidney tissue in five patients with rheumatoid arthritis (RA) who had the profound proteinuria along with the bucillamine (BU) therapy. There was no specific predisposition for BU-induced proteinuria in clinical profiles of five RA patients as age, disease duration, disease activity and co-given drugs except that all of patients were female. Urinalysis revealed proteinuria in all 5 patients (2 patients : nephrotic syndrome) and microscopic hematuria in 4 out of 5 of patients. Renal failure was not observed in all patients. The renal biopsy was performed in 4 patients. The histological findings by light microscopy, fluorescent antibody technique and electron microscopy demonstrated membranous glomerulonephritis (MGN), i.e. positive staining of IgG and electron dense subepithelial deposits in glomerular basement membrane (GBM). Nevertheless, the number of subepithelial deposits in GBM was smaller and the location was scattered compared with idiopathic MGN. The total dosis of BU administration in these patients varied from 7.9 g to 128 g (average : 41.6 g). The causes of BU-induced nephropathy were not known. DLST by BU was, however, positive in 2 out of 5 patients. The outcome of BU-induced proteinuria seemed to be good since one of the patients had the renal failure and the amount of proteinuria was decreased or disappeared by steroid therapy or discontinuation of BU. Thus, the abnormal responses of cellular immunity to this drug might involve in the development of BU-nephropathy.

KW - bucillamine

KW - membranous glomerulonephritis

KW - proteinuria

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85004465061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004465061&partnerID=8YFLogxK

U2 - 10.2177/jsci.13.346

DO - 10.2177/jsci.13.346

M3 - Article

VL - 13

SP - 346

EP - 355

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 4

ER -